戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1       For most species, only a few 2D slices were needed to accurately estimate Sm within 10% of the
2 al capacities, and low regeneration energies are needed to achieve these separations efficiently at s
3 etween the dose of colistimethate that would be needed to achieve a desired Css,avg and creatinine cl
4 mbining multiple sun protection measures may be needed to achieve optimal protection.
5 ; however, at present additional scaffolding is needed to achieve chromosome-level assemblies.
6 ns targeting multiple steps in the continuum is needed to achieve the full beneficial impact of HIV t
7  this structure, it is unknown which factors are needed to activate cumulus specific gene expression.
8               However, innovative approaches are needed to address scale-up issues associated with th
9  detailed estimates of mortality differences are needed to address this public health issue.
10                               Future studies are needed to address whether similar mechanisms contrib
11 rovision to cope with the increasing numbers is needed to address avoidable vision loss.
12                           And, what research is needed to address gaps in our knowledge?
13 ves) will enable the robust stewardship that is needed to address the current crisis of antibacterial
14 ncluding appropriate containment strategies, is needed to address this situation.
15 evelopmental studies have contributed to and are needed to advance clinical goals.
16       Standardized metrics for alert fatigue is needed to advance the field.
17  that a given threshold of physical activity is needed to age optimally and to maximise the 'healthsp
18                                 Further work is needed to aid with the selection of patients most lik
19      Moreover, our data indicate that PI(4)P is needed to anchor Arl8 (Arf-like GTPase 8) and its eff
20                                     Measures are needed to ascertain the source of this compound to w
21 l new endpoints, as well as what new markers are needed to assess the ability of HBV therapeutics to
22                              Further studies are needed to assess the comparative effectiveness of th
23                 Larger scale clinical trials are needed to assess the efficacy of gammaT supplements
24                           More animal models are needed to assess the functions of these genes in viv
25                              Further studies are needed to assess the potential roles of host protein
26                           Prospective trials are needed to assess the predictive value of the circula
27                      Comparative evaluations are needed to assess the suitability of near-road air po
28 iomarkers of progression in patients with RP are needed to assess therapeutic outcomes.
29                However, longitudinal studies are needed to assess this within abstaining smokers.
30                         Further studies will be needed to assess possible herd immunity effects with
31                             Further research is needed to assess generalizability and cost-effectiven
32                             Further research is needed to assess longer-term effectiveness, as well a
33                             Further research is needed to assess longer-term efficacy and adverse eff
34                                Further study is needed to assess safety and long-term clinical outcom
35 ells as well as their microenvironment which is needed to assess the development of diseases.
36 edical properties; however, further research is needed to assess the differences in their pharmacokin
37                        Longer term follow-up is needed to assess the durability of quality-of-life im
38   Critical appraisal of performance criteria is needed to assess whether quality oversight is meeting
39                     Surface anchoring groups are needed to attach molecular units to photoanodes for
40     Better tools to identify indolent tumors are needed to avoid overtreatment.
41                              Further studies are needed to better assess its safety and applicability
42                          Longer-term studies are needed to better assess the safety and clinical impa
43 is still largely overlooked and further data are needed to better describe the group toxicity.
44                              Further studies are needed to better understand the functional underpinn
45 , but use of more precise diagnostic methods is needed to better define epidemiology and underlying e
46                                     Research is needed to better define the dose effect and its inter
47         Innovation in education and training is needed to better prepare future nephrologists for the
48 tudying the role of regional hypermetabolism is needed to better understand its interaction with the
49 nt wide-bandgap (WBG) perovskite solar cells are needed to boost the efficiency of silicon solar cell
50                                   Strategies are needed to care for and counsel patients with cancer
51 sive transfer of antisera and CD4(+) T cells was needed to cause a significant reduction in NP coloni
52 s pathogenesis produced by different viruses is needed to characterize virus and host-specific factor
53                               Future studies are needed to clarify the mechanism and to define the ro
54                                 Better tools are needed to communicate the magnitude of risk to patie
55  hand-helded analyzers: conversion equations are needed to compare the FENO values between these meth
56                          Prospective studies are needed to compare the value of CMR as compared to tr
57                              Further studies are needed to confirm a causal relationship.
58                              Further studies are needed to confirm and refine these recommendations.
59                              Further studies are needed to confirm the antitumour efficacy of the com
60    Additional imaging and pathologic studies are needed to confirm these findings.
61 iseases; however, randomized clinical trials are needed to confirm these findings.
62                              Further studies are needed to confirm these findings.
63 ients undergoing longer duration of sedation are needed to confirm these observations.
64    Validation of this novel predictive score is needed to confirm clinical utility.
65                                     Research is needed to confirm possible interactions of arsenic me
66 sis difficult; therefore, laboratory testing is needed to confirm the diagnosis.
67 ch using more robust epidemiological designs is needed to confirm these findings.
68 ividual, population, and programmatic levels are needed to confront the emerging drug-resistant HIV e
69                  Future policy interventions are needed to continue improvement in dietary quality an
70  the current-day magnitude of each component is needed to create accurate projections of future relat
71                                         This is needed to critically assess whether plasma technology
72                          Prospective studies are needed to define the impact of pretransplant sensiti
73                    Larger prospective trials are needed to define the optimal chemotherapy regimen.
74 ly as human ligands, although future studies are needed to define their potential physiological role
75 clusion of controls for non-specific effects is needed to define a range of additional, effective int
76 arious types of MDR-P. aeruginosa infections is needed to define ceftolozane-tazobactam's place in th
77                                 Further work is needed to define the role different IgG subtypes play
78                               New strategies are needed to design future therapies that target resist
79                  Early and sustained efforts are needed to detect infections and prevent or interrupt
80  .05; power = 80%) estimated that 2982 cases were needed to detect a difference of at least 3%.
81       Future clinical trials focused on AYAs are needed to determine effectiveness of therapies.
82                              Further studies are needed to determine how decreased sterol absorption
83                              Further studies are needed to determine if earlier AVR in these patients
84                        More reliable methods are needed to determine MGMT activity as DNA methylation
85                       Further investigations are needed to determine possible roles for PCNA and othe
86                              Further studies are needed to determine the life course progression of t
87                                      Studies are needed to determine the mechanisms by which coffee m
88 inical trials investigating this combination are needed to determine the optimal treatment strategy f
89                           Therefore, studies are needed to determine the role mGluR5 modulation might
90 ons of observational data, randomized trials are needed to determine the role of MV-PCI in this setti
91            Further rigorous clinical studies are needed to determine their efficacy and safety, as we
92                              Further studies are needed to determine whether specific subgroups of pe
93 ality trials and patient-based meta-analyses are needed to determine whether subpopulations might ben
94                              Further studies are needed to determine whether these can be used as the
95                                      Studies are needed to determine whether these features of PDACs
96                           Larger trials will be needed to determine short-term and long-term safety a
97 l longitudinal follow-up of eyes with drusen is needed to determine if en face OCT imaging can replac
98                Further study of elamipretide is needed to determine long-term safety and efficacy.
99                             Longer follow-up is needed to determine the impact of (18)F-fluciclovine
100                                 Further work is needed to determine the implications of increased tha
101                  BACKGROUND & AIMS: A system is needed to determine the risk of patients with Barrett
102                                More research is needed to determine the validity of inflammation-corr
103                          Long-term follow-up is needed to determine the visual significance of these
104 ption of lipid-rich RUTFs, but more research is needed to determine this.
105 l time and a fixed reference (e.g., GMT) [1] were needed to determine longitude.
106  kidney-specific gene transfer in adult mice are needed to develop new therapies for kidney disease.
107 r studies sharing the same imaging protocols are needed to develop objective models for risk assessme
108                             Further research is needed to develop more effective pediatric fall preve
109                                     Research is needed to develop safe and effective treatments, a pr
110 iscussed, noting areas in which further work is needed to develop the next-generation POPs for practi
111 onates exposed in utero to Zika virus (ZIKV) is needed to develop treatments.
112 re directions of research and reporting that are needed to diminish it.
113 onstrate that exceptionally low temperatures are needed to downregulate FvTFL1 and to make these plan
114                               Future studies are needed to elucidate the provenance and putative neur
115                              Further studies are needed to elucidate the source and epidemiology of P
116                                More research is needed to elucidate HOA risk factors, the mechanisms
117                             Further research is needed to elucidate the reasons underlying persistent
118                    Although further research is needed to elucidate the role of myelin in affecting e
119  referral systems from HEWs and health posts are needed to enable consistent and timely access to Xpe
120                         New global alliances are needed to enable the combination of efforts and reso
121 essfully in rodents, but new infrastructures are needed to enable these strategies in primates.
122                             Novel strategies are needed to enhance muscle repair and function and to
123 rative recovery programs for cancer patients are needed to enhance survival after surgery.
124  traditional redox reactions, but strategies are needed to enhance the performance of molecular catal
125 se.IMPORTANCE Development of novel adjuvants is needed to enhance immunogenicity to provide better pr
126                             Policy solutions are needed to ensure availability of low-cost, essential
127                  Customised service delivery is needed to ensure parity for different geographic and
128                    Antimicrobial stewardship is needed to ensure prompt appropriate clinical action t
129 nts after congenital cardiac catheterization is needed to equitably compare patient outcomes among di
130                    Further follow-up studies are needed to establish the long-term safety of these st
131 ctural properties within hearing organs that are needed to establish tonotopic gradients.
132 ing skin-homing T-cell functional properties are needed to establish whether CLA(+) memory subsets ca
133                                     Research is needed to establish the cost-effectiveness of routine
134 tocin on neural circuits in the hypothalamus is needed to establish the utility of targeting oxytocin
135               Relatively few sampling visits were needed to estimate occupancy and detectability with
136 hat mimic in vivo host-pathogen interactions are needed to evaluate candidate drugs that inhibit bact
137                           However, more data are needed to evaluate sufficient MPA sizes for protecti
138                              Further studies are needed to evaluate the clinical implications of our
139                              Further studies are needed to evaluate the mechanism of and opportunitie
140 iving (223)RaCl2 Further prospective studies are needed to evaluate the potential of the BSI for resp
141           Carefully designed clinical trials are needed to evaluate these potential applications, and
142                     However, further studies are needed to evaluate whether the control of metabolic
143                               Future studies are needed to evaluate whether this uncertainty also inf
144                       Longer follow up would be needed to evaluate the potential use of the visual st
145                     Post-market surveillance is needed to evaluate the real-world clinical effectiven
146 ions are defined biochemically, but a method is needed to evaluate them quantitatively within morphol
147      Therefore, a rapid preclinical approach is needed to evaluate whether simultaneous or sequential
148                             Further research is needed to examine its role in patients with evidence
149 R-pMHC interactions with Kds of </=15 microM were needed to exclude CD45.
150                              Further studies are needed to explain the residual part of the spatial v
151  implies little unmeasured confounding would be needed to explain away an effect estimate.
152 at considerable unmeasured confounding would be needed to explain away an effect estimate.
153 arity, and suggest that a more complex model is needed to explain the effects of PID.
154 neering the variants in model organisms will be needed to explore whether human variants in ANGPTL6 a
155                             Further research is needed to explore optimal donor selection, FT prepara
156 dent replication in population-based studies is needed to extend these findings.
157 ng regulatory networks (RN) and genomic data are needed to extract biological information for a bette
158 eful, nuanced models of language change will be needed to extract deeper signal from the noise of par
159 -Cas9 tools for site-specific genome editing are needed to facilitate further improvements in the BIC
160 ons and policy and enabling environment that are needed to facilitate widespread adaptation may be ve
161  better understanding of the pathology of CP is needed to facilitate improved diagnosis and treatment
162                         New analytical tools are needed to fill the void for detection and visualizat
163 Standardised assessments in diverse settings are needed to fully determine the effect of intervention
164                              Further studies are needed to fully explore the complement of diversity
165 sing on multiple aspects of disease activity are needed to fully understand the natural history of Eo
166  the wide-scale use of neonics, more studies are needed to fully understand their effects on human he
167  the age-data indicate decades or longer may be needed to fully assess the effects of potential subsu
168                   Larger studies in AAs will be needed to fully elucidate the underlying determinants
169 her study using a different luminal promoter is needed to fully support this conclusion.
170 ified research gaps, but specific objectives are needed to further behavioral intervention research.
171  director attitudes, although larger studies are needed to further define program factors affecting a
172 in limited, and future comprehensive studies are needed to further elucidate this disease, which coul
173 ditional high-quality interventional studies are needed to further evaluate the effectiveness of pati
174 psychological, and clinical assessments also are needed to further evaluate the model proposed.
175                          Intervention trials are needed to further examine the effect of flavonoid-ri
176 tional patients and longer follow-up periods are needed to further explore the utility of rituximab i
177 s and processes behind observed improvements is needed to further reduce the burden of injury in Cana
178 behavior change; however, systematic studies are needed to identify and validate targets and to disco
179                                 Better tools are needed to identify patients at high risk of developi
180                                  New methods are needed to identify promising drug candidates earlier
181                 Reliable response biomarkers are needed to identify responders, and conventional imag
182                           Additional studies are needed to identify sources of variability in express
183 well-designed prospective multicenter trials are needed to identify the most effective new agents and
184                           Additional studies are needed to identify the optimal DAA regimen for kidne
185                                  Future work is needed to identify and evaluate innovative culture ch
186                                More research is needed to identify barriers to uptake of CBE at home
187                                More research is needed to identify effects of genetic variation on di
188                       As such, more research is needed to identify level and type (positive/negative
189 ical approach and conclude that further work is needed to identify stable and reliable measures of fi
190                             Further research is needed to identify strategies to improve the quality
191                                Further study is needed to identify the critical practice elements tha
192 r, three anaesthetic-sensitive rho1 subunits are needed to impart full efficacy to the partial GABA a
193                        Integrated strategies are needed to improve access to and uptake of HIV testin
194 rategies targeting humoral immune reactivity are needed to improve long-term intestinal graft outcome
195                            Continued efforts are needed to improve patient selection and procedural/p
196 ces regarding risk of SSI versus risk of AKI is needed to improve clinical decision-making.
197 h type 2 diabetes when pharmacologic therapy is needed to improve glycemic control.
198 n of biliary complications, especially ITBL, is needed to improve the outcomes for DCD grafts.
199 dardized protocols for sampling and analysis is needed to improve the reproducibility and comparabili
200 of clinical subtypes, and further refinement is needed to improve treatment outcomes.
201                                Interventions are needed to increase high-intensity statin use and adh
202                             Targeted efforts are needed to increase the number of medical students ch
203 els that can regulate cytoplasmic Ca(2+) and are needed to induce the expression of a BELL1-like tran
204                                 Rigid matrix is needed to induce rapid nuclear accumulation of the RA
205 complex's second reduction, a third electron is needed to induce the second proton addition from the
206 studies of morphologically different species are needed to infer the principles of organogenesis.
207                                    More data are needed to inform next steps in the responsible stewa
208 th human immunodeficiency virus (HIV) (WHIV) are needed to inform prevention programs for this popula
209 context of the full continuum of iron status is needed to inform approaches to the balancing of benef
210 ic factors underlying neonicotinoid residues is needed to inform evidence-based policy.
211                                     Research is needed to inform firm recommendations on how to prote
212                                More research is needed to inform our knowledge of the role of insuran
213  the neural bases of rehabilitation efficacy is needed to inform therapeutic efforts to improve it.
214 ation of FX by SR-AI, and the presence of FX is needed to interfere with internalization of PTX2.
215                        While further studies are needed to investigate abilities of the PCs of only I
216                                      Studies are needed to investigate associations between risk fact
217                            New animal models are needed to investigate CYP3A functions, especially fo
218                                Future trials are needed to investigate further the use of DSM265 for
219                               Future studies are needed to investigate the role of baseline nutrition
220                              Further studies are needed to investigate the role of specific genes inv
221                                 More studies are needed to investigate the use of bone turnover marke
222                             Further research is needed to investigate how findings from this group of
223                             Further research is needed to investigate the association between these s
224                          A prospective study is needed to investigate the effectiveness of IB in Japa
225                                     Research is needed to investigate the potential of DNA-(de)methyl
226 gation strategies, and examples of efficacy, are needed to justify producer adoption.
227 ivers cells and biologics to IVD injury site is needed to limit the progression of disc degeneration
228         Prevention and management strategies are needed to maintain high quality of care for all pati
229 ctive, accessible biopsychosocial treatments are needed to manage chronic knee pain on a population l
230 rventions to decrease these adverse outcomes are needed to maximize the overall effectiveness of supp
231 sistently violate expectations, new learning is needed to maximize rewards.
232 nent is the Rubisco-containing pyrenoid that is needed to minimise CO2 retro-diffusion for CCM operat
233 smission and missed prevention opportunities are needed to monitor progress toward elimination of mot
234 ion of the PSF framework to the phyllosphere is needed to more fully elucidate plant-microbiota inter
235 lication of these findings in larger samples is needed to more precisely estimate variance explained
236                 In-depth conceptual analyses are needed to move research in religious involvement and
237                                  New studies are needed to optimize and standardize extracorporeal ci
238  on the utility, accuracy, and safety of PLB are needed to optimize its use.
239  interventions to attenuate inflammation may be needed to optimize clinical outcomes in persons with
240                                    More work is needed to optimize its dosing to minimize adverse eve
241    Large collaborations and novel approaches are needed to overcome the genetic heterogeneity of panc
242 and elucidation of its underlying mechanisms are needed to place these results in a clinical perspect
243 ions of future mortality and life expectancy are needed to plan for health and social services and pe
244 alpha (called 'IL-6 cluster signaling' here) was needed to prevent premature induction of interferon-
245  of the long-term influence of these factors is needed to prioritise public health investments to opt
246 rt, cells of different material compositions are needed to produce devices of tailor made characteris
247                              Clinical trials are needed to provide treatment guidance for the group w
248          Therefore, highly sensitive methods are needed to quantify BPA in various matrices including
249 ress scenario), whereas US$371 billion would be needed to reach health system targets in the ambitiou
250  collaboration with the affected populations are needed to realise the benefits of existing intervent
251  and rehospitalization remain unexplored and are needed to reduce readmissions.
252                                     Measures are needed to reduce risk behaviors and increase monitor
253 es and that interdisciplinary collaborations are needed to reduce the harms of gambling.
254  Significant population health interventions are needed to reduce the HF hospitalization burden among
255                               New approaches are needed to reduce the industry's footprint.
256 ve physician-patient communication about CPM is needed to reduce potential overtreatment.
257 strengths of the intermolecular interactions are needed to regulate the formation of different domain
258                    Processing of the R-loops is needed to remove RNA allowing activation-induced (cyt
259         Therapies that stimulate axon growth are needed to repair CNS damage.
260                                Further study is needed to replicate these findings and identify poten
261                             Further research is needed to replicate these findings, determine their c
262           As a result, substantial lead time was needed to resolve procurement and regulatory issues
263                                Interventions are needed to safeguard the health of women after fistul
264 w concepts and strategies of material design are needed to smooth each pivotal step.
265  of the 3-dimensional organization of the IC is needed to specify how the single tonotopic representa
266 asurement, and confirm that lambda < 1/(n-1) is needed to sufficiently suppress multispin effects (wi
267 hes that utilize properties intrinsic to DNA are needed to supplement training based methods and to e
268 solidation (15-19 years), when new responses are needed to support brain maturation, intense social e
269 xperimental systems for new-onset/chronic AD are needed to support rapid therapeutic development, par
270 dent of the nucleotide substitution analyses is needed to support a primary role of genetic drift dri
271                       Shared decision making is needed to support decisions about breast reconstructi
272 rge equilibration method (PQEq) method might be needed to take the effects of Efields into considerat
273 inevitable, and novel therapeutic approaches are needed to target dormant tumors.
274       Prospective randomized clinical trials are needed to test ICD efficacy in patients with an EF >
275 arch with a robust dietary intake assessment is needed to test this hypothesis.
276                       A prospective registry is needed to track the long-term risks of systemic agent
277              Novel therapeutic interventions are needed to treat SZ and DBS is emerging as a potentia
278                               Larger studies are needed to understand the clinical implications of th
279                                    More data are needed to understand the disconnect between efficacy
280                              Further studies are needed to understand the effects of administration o
281  humans and some primates, new animal models are needed to understand the function of APOL1 in vivo W
282                     Spectroscopic approaches are needed to understand the mechanisms by which TRPV1 t
283 igh-resolution structures of metalloamyloids are needed to understand the molecular bases of metal-am
284                              Further studies are needed to understand the sociodemographic and health
285                                 More science is needed to understand how the brain is affected by ear
286                             Further research is needed to understand how these noncardiac complicatio
287                             Further research is needed to understand possible modifiers of these asso
288 of the effect of the environment on the host is needed to understand the disease.
289                                More research is needed to understand the effectiveness of screening a
290 g beetles and P. carabi mites, but more work is needed to understand the functional significance and
291 in isolated case reports; thus, further work is needed to understand the impact of mutation chronolog
292                             Further research is needed to understand the mechanisms influencing micro
293 seen in white populations, but further study is needed to understand whether African American individ
294                                    More work is needed to understand why there was no clinical benefi
295 otent stem (iPS) cell-derived neuronal cells are needed to validate our preliminary findings especial
296 studies with multiple postoperative measures are needed to validate the effect of these potential bio
297                    Additional larger studies are needed to validate the effects of prolonged anakinra
298                              Further studies are needed to validate this finding in Ugandan and other
299                   Future investigations will be needed to validate these therapeutic techniques for p
300 n the treatment of IBD, but further research is needed to validate these approaches.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top